MDGL
Madrigal Pharmaceuticals, Inc.
$511.97
-4.77
(-0.92%)
Mkt Cap
11.83B
Volume
145,521
52W Range
393.61-615
Sector
Healthcare
Beta
-1.00
EPS (TTM)
-12.89 USD
P/E Ratio
-45.32
Revenue (TTM)
1.28B USD
Rev Growth (5Y)
N/A
EPS Growth (5Y)
N/A
Company Description
Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company in the clinical development phase, concentrating its efforts on discovering and commercializing innovative treatments for cardiovascular, metabolic, and liver disorders. Its most advanced drug candidate, resmetirom, functions as a liver-targeted selective thyroid hormone receptor-ß agonist, currently undergoing late-stage (Phase III) clinical trials for managing non-alcoholic steatohepatitis (NASH). The company's pipeline also features MGL-3745, which serves as a secondary or backup compound to resmetirom. Madrigal holds a collaborative agreement with Hoffmann-La Roche, encompassing research, development, and commercialization activities. The company's operations are based out of West Conshohocken, Pennsylvania.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 958.40M | 180.13M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | (288.28M) | (465.89M) | (373.63M) | (295.35M) | (241.85M) | (202.24M) | (83.95M) | (32.81M) | (31.15M) | (26.39M) | (6.84M) | (86.16M) |
| EPS | -12.85 | -21.90 | -19.99 | -17.23 | -14.63 | -13.09 | -4.73 | -2.22 | -2.54 | -5.07 | -401.56 | -30.62 |
| Free Cash Flow | (190.02M) | (457.03M) | (325.71M) | (225.07M) | (184.13M) | (157.90M) | (41.80M) | (25.53M) | (22.44M) | (17.61M) | (71.50M) | (79.07M) |
| FCF / Share | -8.47 | -21.48 | -17.43 | -13.13 | -11.14 | -10.22 | -2.71 | -1.73 | -1.83 | -3.38 | -418.11 | -28.10 |
| Operating CF | (189.55M) | (455.57M) | (324.23M) | (224.86M) | (183.92M) | (157.56M) | (41.62M) | (25.51M) | (22.32M) | (17.61M) | (71.44M) | (78.92M) |
| Total Assets | 1.26B | 1.04B | 640.55M | 362.57M | 273.33M | 287.00M | 442.06M | 485.43M | 192.31M | 41.21M | 68.19M | 100.67M |
| Total Debt | 354.36M | 119.57M | 117.19M | 49.89M | 797,000 | 786,000 | 676,000 | 0 | 0 | 0 | 4.65M | 13.91M |
| Cash & Equiv | 198.69M | 100.02M | 99.92M | 331.55M | 36.27M | 54.00M | 46.70M | 57.38M | 148.63M | 40.50M | 34.97M | 46.02M |
| Book Value | 602.69M | 754.38M | 405.33M | 197.39M | 196.11M | 239.97M | 416.56M | 476.98M | 182.26M | 36.41M | 50.41M | 65.14M |
| Return on Equity | -0.48 | -0.62 | -0.92 | -1.50 | -1.23 | -0.84 | -0.20 | -0.07 | -0.17 | -0.72 | -0.14 | -1.32 |
| Metric | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 364.25M | 311.34M | 321.08M | 287.27M | 212.80M | 137.25M | 103.32M | 62.17M | 14.64M | 0 | 0 | 0 |
| Net Income | (57.94M) | (94.39M) | (58.58M) | (114.19M) | (42.28M) | (73.24M) | (59.42M) | (106.96M) | (151.97M) | (147.54M) | (112.19M) | (98.74M) |
| EPS | -1.99 | -3.25 | -2.57 | -5.08 | -1.90 | -3.32 | -2.71 | -4.92 | -7.10 | -7.38 | -5.68 | -5.34 |
| Free Cash Flow | 19.08M | (171.28M) | (133.07M) | 78.99M | (47.05M) | (88.89M) | (104.68M) | (67.76M) | (140.08M) | (149.51M) | (80.97M) | (85.26M) |
| FCF / Share | 0.65 | -5.90 | -5.93 | 3.51 | -2.12 | -4.02 | -4.77 | -3.12 | -6.54 | -7.47 | -4.10 | -4.61 |
| Operating CF | 23.33M | (167.44M) | (133.46M) | 79.85M | (47.05M) | (88.89M) | (104.49M) | (66.98M) | (134.94M) | (149.16M) | (79.93M) | (84.92M) |
| Total Assets | 1.24B | 1.23B | 1.26B | 1.36B | 1.02B | 996.63M | 1.04B | 1.07B | 1.10B | 1.08B | 640.55M | 237.96M |
| Total Debt | 347.75M | 347.31M | 354.36M | 346.40M | 123.95M | 119.77M | 119.57M | 119.14M | 118.06M | 117.72M | 117.19M | 116.56M |
| Cash & Equiv | 292.73M | 232.19M | 198.69M | 295.69M | 186.19M | 183.65M | 100.02M | 232.68M | 494.60M | 622.52M | 99.92M | 62.05M |
| Book Value | 523.72M | 543.45M | 602.69M | 625.73M | 695.98M | 710.64M | 754.38M | 777.15M | 857.12M | 850.76M | 405.33M | 22.25M |
| Return on Equity | -0.11 | -0.17 | -0.10 | -0.18 | -0.06 | -0.10 | -0.08 | -0.14 | -0.18 | -0.17 | -0.28 | -4.44 |
MDGL News
Allworth Financial LP Buys New Position in Madrigal Pharmaceuticals, Inc. $MDGL
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
Madrigal’s Rezdiffra Hits $1.3B Run Rate as MASH Pipeline Expands
Madrigal's Rezdiffra Hits $1.3B Run Rate as MASH Pipeline Expands
John Paulson's Top Q2 2026 Move: Exiting Agnico Eagle Mines Ltd at a -5.11% Portfolio Impact
Madrigal Appoints John C. Reed, M.D.
Madrigal Pharmaceuticals, Inc. (MDGL) Presents at Canaccord Genuity's 46th Annual Growth Conference Transcript
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
Madrigal Pharmaceuticals to Participate in the Canaccord Genuity 45th Annual Growth Conference
Here Are Tuesday’s Top Wall Street Analyst Research Calls: Apple, CoreWeave, eBay, Exxon Mobil, Intuit, Nebius Group, Palantir Technologies, SK hynix, and More